Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
Infection and Chemotherapy
@article{ART002392502, author={김탁 and 이상오}, title={Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”}, journal={Infection and Chemotherapy}, issn={2093-2340}, year={2018}, volume={50}, number={3}, pages={266-267} }
TY - JOUR AU - 김탁 AU - 이상오 TI - Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia” T2 - Infection and Chemotherapy JO - Infection and Chemotherapy PY - 2018 VL - 50 IS - 3 PB - 대한감염학회 SP - 266 EP - 267 SN - 2093-2340 AB - KW - DO - UR - ER -
김탁 and 이상오. (2018). Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”. Infection and Chemotherapy, 50(3), 266-267.
김탁 and 이상오. 2018, "Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”", Infection and Chemotherapy, vol.50, no.3 pp.266-267.
김탁, 이상오 "Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”" Infection and Chemotherapy 50.3 pp.266-267 (2018) : 266.
김탁, 이상오. Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”. 2018; 50(3), 266-267.
김탁 and 이상오. "Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”" Infection and Chemotherapy 50, no.3 (2018) : 266-267.
김탁; 이상오. Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”. Infection and Chemotherapy, 50(3), 266-267.
김탁; 이상오. Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”. Infection and Chemotherapy. 2018; 50(3) 266-267.
김탁, 이상오. Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”. 2018; 50(3), 266-267.
김탁 and 이상오. "Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”" Infection and Chemotherapy 50, no.3 (2018) : 266-267.
Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”